Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Wat is de waarde van uniQure?
Volgen
~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington, MA ~ Preparation Underway for Late-Stage Development in Hemophilia B ~ Cost Savings Expected to Extend Cash Resources into 2019 ~ Company to Host Investor Conference Call Today at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the completion of a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value. As a result of this initiative, the Company will prioritize programs in hemophilia B, Huntington’s disease and those associated with its landmark collaboration with Bristol-Myers Squib (BMS) in cardiovascular disease. Additionally, the Company will restructure its research and development organization in the Netherlands and consolidate manufacturing in the United States. These actions are expected to reduce operating expenses and create a more efficient company focused on the successful and timely development of gene therapies for patients with serious unmet medical needs. As part of its effort to focus resources on key priorities, uniQure has initiated discussions with its collaborator regarding the potential discontinuation of licensing discussions for AMT-110 for the treatment of Sanfilippo B, and will pursue partnering opportunities for its academic-sponsored program in Parkinson’s disease. uniQure expects to realize €5 to €6 million of annualized cost savings in personnel and other related operating expenses as a result of the elimination of approximately 50 to 60 positions, or 20% to 25% of global headcount, by the end of 2017. Additionally, the Company expects to further reduce planned operating expenses by €11 to €15 million over the next two years through the focusing of its pipeline. Based on its strong cash position and the above actions, uniQure believes its existing cash resources will be sufficient to fund operations into 2019. “The strategic restructuring brings enhanced focus to our pipeline, streamlines operations and improves our financial strength,” stated Matthew Kapusta, interim chief executive officer of uniQure. “We are committed to the timely development of our programs in hemophilia B and Huntington’s disease, as well as the support of our collaboration with BMS. Along with our investigators and collaboration partner, we are enthusiastic about the interim data from our ongoing Phase I/II study of AMT-060 in hemophilia B and will allocate necessary resources to expedite bringing AMT-060 to market, with commercial manufacturing capabilities in our state-of-the-art U.S. facility which is already in place.” “We are confident that these efforts will significantly streamline operations and position us well for the future,” Mr. Kapusta added. “We are grateful for the contributions that the employees affected by this outcome have made to uniQure, and we will be supporting them throughout this transition.” Key Outcomes of the Strategic Review Pipeline Prioritization uniQure has decided to prioritize the following programs within its gene therapy pipeline: Pursue as top priorities the clinical development of its product candidates in hemophilia B and Huntington’s disease. The Company intends to initiate a pivotal trial in hemophilia B pending discussions with regulatory authorities and to file an investigational new drug (IND) application for Huntington’s disease following the completion of ongoing IND-enabling studies. Provide greater focus on new product generation, with an emphasis on liver-directed diseases. This includes the internal development or in-license of new product candidates in rare and orphan diseases that can leverage the Company’s next-generation vector and promoter platform and manufacturing capabilities. Advance uniQure’s collaboration with BMS in cardiovascular diseases as a top research priority, specifically focused on the advancement of S100A1 in congestive heart failure. Evaluate options for its gene therapy programs targeting Sanfilippo B and Parkinson’s disease, including partnering opportunities. Two of the four patients in the ongoing Phase I/II clinical trial in Sanfilippo B have completed their 30-month evaluations, and the 30-month data on all four patients in the study are expected to be available for presentation in the first quarter of 2017. Regarding the academic-sponsored trial in Parkinson’s disease, uniQure will evaluate partnership opportunities to accelerate completion of the ongoing study and further develop the program. Consolidate Global Manufacturing uniQure will consolidate all GMP manufacturing at its Lexington, MA facility. The Lexington facility is fully operational and has the capability of scaling up to 2,000L capacity, which uniquely positions the Company for late-stage development and commercialization of its gene therapy products. The Company will maintain a smaller, but fully integrated research and development organization in Amsterdam, the Netherlands. The team is expected to move into a new facility in the first half of 2017. Streamline Research and Development The previous organizational structure based on therapeutic areas of focus is being eliminated. As a result of this change, Deya Corzo, M.D., senior vice president of the liver and metabolic therapeutic area, and Charles Richard, M.D., Ph.D., senior vice president of the central nervous system therapeutic area are transitioning their responsibilities and will be leaving the Company by the end of the year. Christian Meyer, M.D., Ph.D., chief medical officer, will assume full responsibility for advancing the company’s hemophilia B gene therapy program. Harald Petry, Ph.D., chief scientific officer, will continue to lead uniQure’s preclinical research, including IND-enabling studies in Huntington’s disease. “We have simplified the structure of the Company to drive focus and provide for a strong foundation upon which to execute our key priorities,” stated Philip Astley-Sparke, chairman of the uniQure Board of Directors. “Further details on how we expect to position our hemophilia program will be provided after we have met with regulatory authorities early next year to discuss our plans for a pivotal study. We will further direct capital into programs that we believe will create near-term value, as well as continue to leverage our core assets, including next-generation vector development and best-in-class manufacturing capabilities.” Conference Call Information uniQure will host a conference call today, November 15, 2016 at 8:30 a.m. ET to discuss this announcement. To access the live call by phone, dial (877) 280-2296 (United States) or +44 (0)20 3427 1917 (international); the conference ID is 4243017. The call may also be accessed through the Investors section of the Company’s website at www.uniQure.com. Following the live webcast, a replay of the call will be available at the same location through November 30, 2016.
Prof. Dollar schreef op 28 september 2016 23:15 :
[...]
De uitspraak '[..] we
currently have two manufacturing facilities' van Kapusta geeft een mogelijke hint. Mijn verwachting is daarom dat ze de productiefaciliteit in Amsterdam sluiten. Evenals breedte onderzoek want dat kunnen ze uitbesteden aan universiteiten en partners.
Dus research in academia, development in Nederland en manufacturing, distributie en commercie in de VS.
Verder strakke focus op het productieplatform (kennis en ontwerp van proces en toediening), vectorplatform (kennis en kunde van vector, promotor, capsid) en portfolio (kennis en ervaring van targets).
Nou Prof je full hit !! Het communicatie-kwartet heeft´t er maar druk mee...: AMSTERDAM (AFN) - Biotechnologiebedrijf UniQure schrapt tientallen banen in Nederland. Dat maakte het voormalige Amsterdam Molecular Therapeutics (AMT) dinsdag bekend. UniQure, dat een notering heeft aan de aandelenbeurs in New York, verhuist zijn productie grotendeels naar de Verenigde Staten. Bij die reorganisatie verdwijnen in totaal vijftig à zestig banen, waarvan het merendeel in Nederland. Een woordvoerster van het bedrijf kon niet aangeven hoeveel banen er exact in Nederland verdwijnen. UniQure legt zich in Nederland voortaan toe op onderzoek en ontwikkeling. De werkgelegenheid op dat vlak wordt door de reorganisatie niet geraakt. UniQure biedt momenteel werk aan 175 medewerkers in Amsterdam en 70 in Lexington, in de Amerikaanse staat Massachusetts.
Om 14.30 u. is een Conference Call Strategic Review Outcome gestart
Investeerders zien altijd graag bezuinigingen, mits de focus naar de toekomst wijst en productie/ontwikkeling niet in het gedrang komt. Cashflow tot 2019, prima. Ook de amerikanen zullen sneller intresse tonen wanneer zij meer veramerikaniseren.
Toch eigenlijk goed nieuws,we wisten + 3 jaar geleden al dat ze 10.000 vierkante meter in amerika gingen bouwen,nu is het zover ,hier mensen eruit daar weer uitbouwen.Nu maar hopen dat vanaf morgen het aandeel in amerika weer gaat stijgen naar ouwerwetse hoogten van 2 de paasdag 2015....................
Met een GROTER dan gemiddeld volume een rode candle. Steun 7,50 Weerstand 8,10 Sk 7,75 Het aandeel is uit de overbought situatie. Staat nog in de up trend.
cqtvld schreef op 15 november 2016 22:32 :
Toch eigenlijk goed nieuws,we wisten + 3 jaar geleden al dat ze 10.000 vierkante meter in amerika gingen bouwen,nu is het zover ,hier mensen eruit daar weer uitbouwen.Nu maar hopen dat vanaf morgen het aandeel in amerika weer gaat stijgen naar ouwerwetse hoogten van 2 de paasdag 2015....................
Vind ik ook Toch reageert de uniqure koers zeer ouderwetsch (Vroeger gingen beleggers zich zorgen maken bij besparingen, tegenwoordig kickt elke belegger daarop en gaat de koers 10 van de 10 keer omhoog. Dit is uniqure .. i know.
DeZwarteRidder schreef op 5 december 2012 15:03 :
[...]
Wil ik deze aandelen (UniQure) hebben.....????
Nee, natuurlijk niet, ik zit in Galapagos.
Leuk om dit soort berichten terug te zien.....
DeZwarteRidder schreef op 30 november 2012 14:19 :
[...]
Kasstroom ontwikkelen...???
Je bent zeker een grapjas.
Dit bedrijf zal nog vele, vele jaren geen positieve kasstroom hebben en zeer waarschijnlijk binnenkort weer nieuw geld nodig hebben.
Ben benieuwd of je dan nog zo blij bent, als je geld bij moet storten of als je bezit weer fors verwaterd.
Als je wil weten hoe het afloopt; zie Pharming.
4 jaar later.......
DeZwarteRidder schreef op 19 december 2012 09:31 :
Ik kan alle bezitters van UniQure van harte aanbevelen om hun aandeeltjes te verkopen en om te wisselen in Galapagos (die heb ik net bijgekocht).
Deze ruil levert veel geld en veel minder ergernis op in de nabije en verre toekomst.
Kijk eens hoe lang het geduurd heeft bij winnaar Crucell voordat er enige winst gemaakt werd, dat zal bij UniQure nog veel langer duren (als ze niet voortijdig failliet gaan).
Tja....
DeZwarteRidder schreef op 19 december 2012 10:24 :
[...]Galapagos kans op succes: 90%
UniQure kans op succes: 5%
En met succes bedoel ik winst.
Geen gekke voorspelling voor iemand die geen verstand heeft van biotech.....
Grote jongen. Succes verder op het Galapagos forum.
Fartknock schreef op 16 november 2016 05:27 :
Grote jongen. Succes verder op het Galapagos forum.
Ik zit op het MDxHealth-forum; dit aandeel biedt zeer grote (overname)kansen bij een beperkt risico en dat kom je zelden tegen in de bio-tech.
Hey .. de zwarte riddert one mens show .. altijd grappig. Enfin de trumppump is weer voorbij zag ik, ploff terug naar de 7, kortom het geduld wordt weer aardig op de proef gesteld. Ik had mijzelf nog voorgenomen op 1/3e er boven de 8.20 uit te knikkeren .. hebberigheid kent geen tijd.
Met GROOT volume een rode candle. Steun 6,75 Weerstand 7,48 Sk 7,02 Aandeel is weer in de down trend.
Chardan Capital reissued their buy rating on shares of uniQure NV (NASDAQ:QURE) in a report released on Tuesday. The brokerage currently has a $12.00 price target on the stock. Zelfs de "buys" doen pijn ...
T. Montana schreef op 17 november 2016 11:49 :
Chardan Capital reissued their buy rating on shares of uniQure NV (NASDAQ:QURE) in a report released on Tuesday. The brokerage currently has a $12.00 price target on the stock.
Zelfs de "buys" doen pijn ...
Jullie kunnen beter omruilen naar MDxHealth, dan heb je tenminste nog een kans om je verliezen ooit terug te verdienen.....
T. Montana schreef op 17 november 2016 11:49 :
Chardan Capital reissued their buy rating on shares of uniQure NV (NASDAQ:QURE) in a report released on Tuesday. The brokerage currently has a $12.00 price target on the stock.
Zelfs de "buys" doen pijn ...
de 1 zegt 36$ de ander 12$ en alles wat daar tussen ligt .. voorlopig heeft niemand het bij het rechte eind.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
921,46
-0,34%
EUR/USD
1,0674
-0,61%
FTSE 100
8.160,02
-0,04%
Germany40^
18.044,50
-1,21%
Gold spot
2.329,85
+1,23%
NY-Nasdaq Composite
17.667,56
+0,34%
Stijgers
Dalers